Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphic Holding, Inc. - Common Stock (NQ:MORF)

56.99 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Morphic Holding, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
Short Volatility Alert: Morphic Holding, Inc.
On Thursday, shares of Morphic Holding, Inc. (NASDAQ: MORF) experienced volatile short activity. After the activity, the stock price went up +4.69% to $22.53. The overall... 
Via Benzinga
Looking Into Morphic Holding's Return On Capital Employed
Benzinga Pro data, Morphic Holding (NASDAQ:MORF) reported Q1 sales of $2.38 million. Earnings fell to a loss of $31.48 million, resulting in a 47.11% decrease from last quarter. 
Via Benzinga
Morphic Holding: Q1 Earnings Insights
Morphic Holding (NASDAQ:MORF) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Morphic Holding
Over the past 3 months, 4 analysts have published their opinion on Morphic Holding (NASDAQ:MORF) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Wells Fargo Maintains Overweight Rating for Morphic Holding: Here's What You Need To Know
Wells Fargo has decided to maintain its Overweight rating of Morphic Holding (NASDAQ:MORF) and lower its price target from $81.00 to $79.00. Shares of Morphic Holding are trading down 3.76% over the... 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
Via Benzinga
Stocks Flounder As Wall Street Rotates Out Of Tech
Big Tech stocks are struggling ahead of several key earnings reports. 
Via Talk Markets
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday... 
Via Benzinga
CFO And COO Of Morphic Holding Trades $2.2M In Company Stock
Marc Schegerin, CFO And COO at Morphic Holding (NASDAQ:MORF), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Past Week's Notable Insider Buys Include AppLovin, Cricut, Biotechs, And More
With earnings-reporting season all but over, many insiders are free once more to buy or sell shares. Here are a few of the most noteworthy insider purchases that were reported in the past week. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Upgrades 
Via Benzinga
The Past Week's Notable Insider Buys Included AppLovin, Cricut, Biotechs And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders were making return trips to the buy window... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study
Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD). The data... 
Via Benzinga
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
Via Talk Markets
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
Exposures Product Safety
Notable Insider Buys Of The Last Week: Bumble, Coty, Peloton Interactive, More
Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near all-time highs. Some return buyers were among the insiders... 
Via Benzinga
Is Morphic Holding a Buy?
This experimental biotech has more than tripled investors' money over the past 12 months. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS